The FDA's complete response letter for Disc Medicine's orphan drug, which questioned the clinical relevance of a biomarker, is causing widespread concern. This decision challenges the long-standing paradigm of using biomarkers for accelerated approval, a cornerstone of development for rare diseases.

Unlike existing MS therapies that primarily manage inflammatory relapses, Immunic's experimental drug has a dual mechanism. It both curbs inflammation and directly protects neurons from cell death, addressing the underlying disability progression that current treatments largely fail to stop.

Minimal Residual Disease (MRD) negativity is now recognized by regulators as a surrogate endpoint in oncology. Because it is considered 'reasonably likely to predict progression-free survival,' this shift allows drug developers to use MRD data to support accelerated approval pathways, expediting the availability of new therapies.

For its alpha-1 antitrypsin deficiency program, Beam aligned with the FDA on an accelerated approval pathway based on a surrogate endpoint: restored alpha-1 protein levels. This strategy allows for faster market entry, with a longer-term confirmatory trial measuring clinical outcomes like lung and liver function running in parallel.

A patient advocate with Huntington's explains that a multi-year delay for a promising gene therapy isn't merely a procedural hurdle. For patients in early stages, there is a "short window where my brain is healthy enough to benefit." A regulatory reset requiring a new 3-5 year trial means they will lose their eligibility and, effectively, their lives.

Instead of waiting years for traditional vision preservation data, Complement Therapeutics' trial prospectively uses novel endpoints like ellipsoid zone attenuation and focal microperimetry. These measures are designed to show a signal of efficacy earlier and correlate better with functional outcomes, addressing a key challenge in slowly progressing diseases.

The FDA is abandoning rigid, fixed-length clinical trials for a "continuous" model. Using AI and Bayesian statistics, regulators can monitor data in real-time and approve a drug the moment efficacy is proven, rather than waiting for an arbitrary end date, accelerating access for patients.

After a decade on the market and multiple shifts in endpoints, Sarepta's definitive Phase 3 study for its DMD drugs failed. This outcome casts doubt on the entire accelerated approval framework for slowly progressive diseases, where surrogate endpoints may not translate to clinical benefit, leaving regulators and patients in a difficult position.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.